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Abstract
Background: Phosphatase of regenerating liver-3 (PRL-3) is a member of the novel phosphatases of regenerating liver
family, characterized by one protein tyrosine phosphatase active domain and a C-terminal prenylation (CCVM) motif.
Though widely proposed to facilitate metastasis in many cancer types, PRL-3’s cellular localization and the function of its
CCVM motif in metastatic process remain unknown.
Methodology/Principal Findings: In the present study, a series of Myc tagged PRL-3 wild type or mutant plasmids were
expressed in B16F1 melanoma cells to investigate the relationship between PRL-3’s cellular localization and metastasis. With
immuno-fluorescence microcopy and cell adhesion/migration assay in vitro, and an experimental passive metastasis model
in vivo, we found that CCVM motif is critical for the localization of PRL-3 on cell plasma membrane and the lung metastasis
of melanoma. In particular, Cystine170 is the key site for prenylation in this process.
Conclusions/Significance: These results suggest that cellular localization of PRL-3 is highly correlated with its function in
tumor metastasis, and inhibition of PRL-3 prenylation might be a new approach to cancer therapy.
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Introduction
Phosphatase of regenerating liver (PRL)-3 is a phosphatase with
small molecular weight (22 kDa). Recently, this member of the
PRL family has been found to play a critical role in the processes
of tumor initiation and development, such as cancer cell invasion
and migration, tumor angiogenesis and metastasis [1–4]. PRL-3
has also been proposed as a biomarker for advanced malignancy in
gastric cancer, ovarian cancer, colorectal carcinoma etc. and
implicates poor clinical outcome [5,6]. The potential great
importance of PRL-3 in malignant tumors could also be supported
from research insights into its structure.
The three members of PRL class share at least 75% amino acid
sequence similarity [7–9]. With the other two members (PRL-1
and PRL-2), PRL-3 shares the family’s common structure of two
functional domains. The catalytic domain constitutes one critical
motif for PRL-3 and functions as a protein tyrosine phosphatase
(PTP) for dephosphorylation similar to most other dual phospha-
tases [8]. Though its specific substrate in vivo has not been clearly
identified yet, a number of papers have addressed the importance
of this PTP domain of PRL-3 or other proteins in promoting
cancer cell growth, invasion and metastasis [10,11]. Our previous
research also indicated that PRL-3 with inactive PTP domain
reduced the migratory ability of tumor cells [3]. The other
functional domain of PRL-3 is the CCVM motif for prenylation.
In contrast to the known effects of the PTP domain as mentioned
above, it is unknown if the CCVM motif contributes to the
progress of cancer metastasis.
Prenylation is a common post-translational modification for
proteins that are targeted to membranes or other interacting factors
[12]. The CAAX sequence on the C-terminal of PRL-3 constitutes
a conserved feature of thiskind of protein family. The recognition of
prenylation motifs such as CAAX, XXCC, XCXC and CCXX by
farnesyltransferase (FT) or geranylgeranyltransferase (GGT), aids in
the correct localization of a variety of proteins to specific sites within
the cell and enables participation in their relevant signal
transduction pathways [13,14]. Prominent members of the family
such as Ras and Rab, including H-Ras, K-Ras and N-Ras, are
prenylated resulting in targeting to plasma membrane or Golgi for
their cellular function in tumor proliferation and anti-apoptosis.
Likewise, Rho-A, Rho-B and Rho-C localize to plasma membrane
afterthis prenylation resultinginpromotion of tumormetastasis and
angiogenesis [12,15,16].
There is no current consensus on the subcellular localization of
PRL-3. Zeng et al. [17] reported that PRL-1, -2, and -3 were
targeted to plasma membrane and the early endosomes while a
small fraction of unprenylated molecules were localized in the
nucleus. In contrast other researchers such as Fiordalisi et al. [18]
demonstrated that PRL-3 localized in endomembranes. Since
cellular localization could establish a causal link with the molecular
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elucidated. Therefore, here we explored the role of prenylation of
the CCVM motif in PRL-3’s cellular localization and in the
process of tumor cell metastasis. Consistent with our recent work
demonstrating the important role of PRL-3 in melanoma
metastasis [3,19], the data presented here offer new insight to
the functional role of PRL-3 stressing the importance of
subcellular localization in the regulation of metastasis.
Results
Construction of Myc-PRL-3 fusion expression vector and
expression in B16F1 murine melanoma cells
To investigate the subcellular localization of PRL-3, we
constructed wild-type (WT) and mutant Myc-PRL-3 fusion
expression vectors. The mutant vectors consisted of mutations to
the amino acids 170 to 173 of PRL-3 C-terminal CCVM motif,
including Myc-PRL-3-C170S (C at 170 replaced with S), Myc-
PRL-3-C171S (C at 171 replaced with S), Myc-PRL-3-C170/
171S (both C at 170 and 171 replaced with S) and Myc-PRL-3-
CCVM-del (without the CCVM structure in the C-terminal)
(Fig. 1A and B). A high percentage of the B16F1 cells expressed
GFP 24 hours after transient transfection with pEGFP-N1
indicating efficient transfection (Fig. 1C). Meanwhile, protein
extracts of B16F1 cells transfected with PRL-3-WT or mutations
were analyzed with c-Myc antibody by Western blot. As shown in
Fig. 1D, Myc-PRL-3-WT and their mutations were efficiently
expressed in B16F1 murine melanoma cells.
Subcellular localization of PRL-3 with a critical site of 170
cysteine
The subcellular localization of PRL-3 was observed by immuno-
fluorescent staining with c-Myc antibody 24 hoursfollowing transient
transfection of B16F1 cells with PRL-3-WT or mutation vectors.
PRL-3-WT and PRL-3-C171S mutants were located on cytoplasmic
membrane (Fig. 2). In contrast, PRL-3-CCVM-del was mostly found
within the cytosol. Likewise, PRL-3-C170S and PRL-3-C170/171S
were also localized to the cell cytosol.
Increased adhesion and migration of B16F1 transfectant
cells with relation to cysteine170 of PRL-3 and inhibition
by FTI-277
The adhesion capabilities of B16F1 cells were analyzed
24 hours following transfection with PRL-3-WT or the mutants.
Thirty minutes after plating, the adhesion capability to fibronectin
of B16F1 cells transfected with PRL-3-WT and PRL-3-C171S was
significantly increased to 48% and 53%, respectively, compared
with 21% adhesion of cells treated with mock vector (Fig. 3A). In
contrast, transfection with PRL-3-CCVM-del, PRL-3-C170S and
PRL-3-C170/171S had little effect on the cell adhesion to
fibronectin (Fig. 3A). Similar to the results in adhesion assay,
transfection of B16F1 cells with PRL-3-WT and PRL-3-C171S
resulted in a 2.7- and 2.5-fold, respectively, enhanced migration to
the under surface compared to cells transfected with mock vector
24 hours following plating (Fig. 3C). However, transfection with
PRL-3-CCVM-del, PRL-3-C170S and PRL-3-C170/171S had
no such effects on cellular migration (Fig. 3C).
Figure 1. Construction of Myc-PRL-3 fusion expression vector and expression in B16F1 murine melanoma cells. (A) Schematic
drawing of pTARGET-Myc-PRL-3 expression vector. (B) Schematic representation of Myc-PRL-3 mutations. Mutations were constructed from
pTARGET-Myc-PRL-3-WT by PCR. (C) Photographs of transfection efficiency of B16F1 cells. B16F1 cells were transfected with pEGFP for 24 hours and
then observed with fluorescent microscopy (right); same view as the right but with a light microscopy (left). (D) Level of Myc-PRL-3 was detected by
Western blot. Results shown are representative of three independent trials.
doi:10.1371/journal.pone.0004450.g001
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broad class of proteins containing a CAAX motif, which is often
modified by post-prenylation. To determine the role of prenylation
in PRL-3-induced cell adhesion and migration the farnesyltrans-
ferase inhibitor, FTI-277 was used. Pretreatment of B16F1 cells
transfected with PRL-3-WT with FTI-277 (1 mMo r2mM) for
18 hours of the 24 hour post transfection period resulted in a
reduction of cell adhesion to 32% and 16% as compared with 50%
of untreated PRL-3-WT transfected cells (Fig 3B). Likewise, the
migratory capability of PRL-3-WT transfected B16F1 cells was
decreased by 55% and 82% following FTI-277 (1 mMo r2mM)
treatment, respectively, as compared with untreated PRL-3-WT
cells (Fig. 3D).
Metastatic tumor formation of B16F1 cells transfected
with PRL-3-WT or mutants
C57BL/6J mice were injected with B16F1 cells transfected with
PRL-3-WT, mutants or mock vector (Fig. 4). Twenty days later,
Figure 2. Intracellular localization of PRL-3. B16F1 melanoma cells were transiently transfected with wild type and mutated Myc-PRL-3
expression vectors. Twenty-four hours after transfection, cells were fixed with 4% paraformaldehyde and stained with anti-Myc primary antibody and
FITC labeled secondary antibody. Myc-PRL-3 wild type and mutations were detected under fluorescence microscopy (4006). Nuclei were
counterstained with 4, 6-diamidino-2-phemylindole (blue). Pictures shown are representative of three independent trials.
doi:10.1371/journal.pone.0004450.g002
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with PRL-3-WT and PRL-3-C171S transfected cells, with average
nodule number of 17 and 20, respectively (Fig. 4B), and severe
tumor cell infiltration could be observed with histological
examination (Fig. 4A). In contrast, only a slight pulmonary
metastasis with an average nodule number of 4, 4, 5 and 5 was
detected in mice injected with cells transfected with mock vector,
PRL-3-CCVM-del, PRL-3-C170S or PRL-3-C170/171S, respec-
tively (Fig. 4B). In these mice there was only alleviative tumor cell
infiltration (Fig. 4A). In addition, two of six mice carrying PRL-3-
WT transfected cells and three of six injected with PRL-3-C171S
transfectants had metastatic lesions in both of the mesentery lymph
nodes and the lung (Fig. 4C). No other metastatic sites were
observed in liver, kidney or colon.
Discussion
Our previous studies showed that the phosphatase activity of PRL-
3 was involved in the promotion of tumor metastasis [3]. However,
little is known about the role of PRL-3’s cellular localization in this
tumorigenic process. In order to explore the relationship between
PRL-3’s subcellular localization and its metastatic function, we
utilized an over-expression system with Myc fusion protein. We
amplified PRL-3 gene from mice skeleton muscle and constructed
Myc-PRL-3 wild type and four mutant fusion expression vectors
(Fig. 1A). The two cysteines of PRL-3 CCVM were mutated to
serines (Fig. 1B) to specify the exact crucial site in tumor migration.
Proteins with CAAX motif are often farnesyled or geranylger-
anyled, which adds a long hydrophobic fatty acid chain to the
Figure 3. Effects of PRL-3-WT/mutations and prenylation inhibitor FTI-277 on B16F1 melanoma cells adhesion and migration
ability. (A) B16F1 cells transfected with wild type or mutated Myc-PRL-3 expression vectors and (B) PRL-3-WT transfected cells pretreated with 1 mM
or 2 mM FTI-277 for 18 hours were seeded into the wells of 96-well plates coated with fibronectin (10 mg/ml). After incubation for 30 minutes at 37uC,
non-adherent cells were gently washed away. The amount of the adherent cells was determined at 592 nm after crystal violet staining. Data are
mean6SEM of three independent experiments and each experiment includes triplicate sets. (C) A single-cell suspension (100 ml, 1610
6 cells/ml) of
cells was plated into the upper wells of Transwell inserts containing 8 mm pore polycarbonate membranes pre-coated with fibronectin on the under
surface. Cells were allowed to migrate for 24 hours at 37uC, and then fixed, stained with crystal violet and counted. Quantitative analysis of the
number of the cells migrated to the lower side of the membrane is shown. (D) Treatment with FTI-277 inhibits the migration of B16F1 melanoma
cells. B16F1 cells were transfected with PRL-3-WT and incubated with FTI-277 1 mMo r2mM for 18 hours before plated into the upper wells of
Transwell inserts, which still contain different concentrations of FTI-277. All Data are mean6SEM of three independent experiments. *, P,0.05; **,
P,0.01, vs. mock vector for (A) and (C) and vs. PRL-3-WT expression vector for (B) and (D).
doi:10.1371/journal.pone.0004450.g003
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Though various proteins of the CAAX family depend on such
modifications for correct localization, they can be targeted to
different subcellular sites [21,22]. In our current study, with the
effective transfection system shown in Fig. 1, PRL-3 wild type and
the mutant vectors were introduced into B16F1 to determine the
subcellular localization of PRL-3. As shown by immunofluorescent
microscopy, wild type PRL-3 was localized to cell cyto-membrane,
while the C170S mutation resulted in the diversion of the majority
of the protein to the whole cytosol. However, such whole cytosol
distribution did not happen in the cells transfected with PRL-3-
C171S mutants. Although the specific subcellular localization of
PRL-3 was not examined in this work, our current data suggested,
at least that PRL-3 could locate on the plasma membrane of
murine melanoma cells and further, Cys170 was the key site for its
localization while Cys171 contributed little to this progress. These
results may be inconsistent with some previous conclusions. For
example, Fiordalisi et al. [18] transfected colon cancer cell line
SW180 with GFP-PRL-3 fusion protein and found PRL-3 located
on the endoplasts and recticulum membrane while its SAXX
mutants were observed in the nucleus. Zeng et al. [11] reported
that over-expression of GFP-PRL-3 fusion protein in CHO cells
resulted in protein localization to certain regions of plasmic
membrane such as membrane ruffles, protrusions and some
Figure 4. Effect of PRL-3-WT/mutations on B16F1 melanoma cells metastasis in vivo. B16F1 melanoma cells transfected with mock vector,
wild type or mutated Myc-PRL-3 expression vectors were injected intravenously into C57BL/6J mice via tail vein. After 20 days, the mice were
dissected and analyzed for metastasis. (A) Representative examples of lungs from the mice. The top and middle panels show the stereo micrographs
of lungs. The lower panels show the histological photomicrographs of lung section stained with hemotoxylin and eosin (1006). NL, normal lung
tissue; T, metastatic tumor lesions. (B) Quantitative evaluation of macroscopically detectable lung metastases. After fixation in Bouin’s solution, the
number of macroscopically visible metastases on the lung surface was quantified. (C) Representative example of mesentery lymph node metastatic
site. Data are mean6SEM of six mice. **, P,0.01, vs. mock vector.
doi:10.1371/journal.pone.0004450.g004
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explained by cell type or fusion protein system specificity
mediating localization due to differences in cell signaling and
protein interaction. In previous studies [11,18], the 22 kDa PRL-3
was fused to GFP of 27 kDa [23], facilitating localization tracing,
but possibly inducing side effects on the PRL-3’s localization in
normal status. Since GFP was bigger than PRL-3 in molecular
size, it might produce steric hindrance for correct localization of
PRL-3. The PRL-3’s localization observed in our study could be
supported from the reports of Bardelli et al. [2] in which over
expression of HA-PRL-3 in colon cancer cells CRC resulted in cell
plasmic membrane localization of PRL-3. It still needs to be
determined whether PRL-3 would localize to other membrane
structures within the cell.
We then determined the role of PRL-3 prenylation on the cancer
cell adhesion and migration ability in vitro. Compared to the control
group transfected with mock vector, PRL-3 transfectants with PRL-
3-WT and PRL-3-C171S had an elevated ability of adhesion and
migration to strata of fibronectin (Fig. 3A and C). In contrast the
other two mutants, PRL-3-C170S and PRL-3-C170/171S, had no
effectontherateofadhesionormigration.Wethushypothesizethat
PRL-3 localizing to cell cyto-membrane is indispensable for its
function in cancer metastasis via participation in the signal
transduction pathway on the inner side of the membrane. In fact,
by using a yeast two-hybrid system to identify integrin a1 on cell
membrane as a PRL-3-interacting protein, Peng et al. [24]
demonstrated that PRL-3 could down-regulate the tyrosine-
phosphorylation level of integrin b1, hence activating the MAPK
pathway. Furthermore, we found that C170S mutants showed a
strongly reduced ability of cell adhesion and migration, and
treatment with the prenylation transferase inhibitor FTI-277 also
decreased the ability of PRL-3-WT transfected B16F1 cells (Fig. 3B
and D). This result supported a model of Cys170 prenylation in
normal PRL-3 function. At the same time, we found that when
treated with high concentration (2 mM) of FTI-277, PRL-3-WT
transfected B16F1 cells showed even lower migration ability
compared with mock vector, suggesting that FTI-277 might inhibit
some other molecules’ function. In fact, the most proteins of the
CAAX family are also oncogenes, such as Ras and Rho super-
family [14,25]. For this reason, investigations into the mechanisms
of farnesylation and the drug-screening for prenylation transferase
inhibitors are becoming a new hotspot of pharmacology. A number
of such inhibitors are already in phase III clinical trials as potential
new generation of agents for anticancer treatment with their low
toxicity and high efficiency [26]. Our current study offers PRL-3 as
a new target for this kind of medicine treatment.
Since tumor metastasis is a highly complex, multi-step progress,
the in vivo behavior of wild type PRL-3 and its mutation
transfectants’ were further examined. In an experimental passive
tumor metastasis model, we found that few nodules were formed in
the lung of mice injected by mock vector transfectants. Such
pulmonary metastasis was apparently increased in those seeded by
PRL-3-WT and PRL-3-C171S mutants. In contrast, mice with the
other mutant-transfected B16F1 showed low tumorigenic behavior
similar to the control group (Fig. 4A and B). In addition, apparent
mesentery lymph node metastatic lesions were also observed inmice
injected with PRL-3-WT and PRL-3-C171S mutants (Fig. 4C), but
not those with mock vector, PRL-3-CCVM-del or the other two
mutants. These results further support our hypothesis that PRL-3’s
localization to plasma membrane directed by Cys170 prenylation is
crucial for its function in promoting tumor metastasis.
In summary, our current study demonstrated the critical role of
CCVM motif for PRL-3 intracellular localization and promotion of
tumor metastasis, of which Cys170 was the key amino acid for
prenylation. The localization of PRL-3 to cell cyto-membrane was
highly correlated with its function in the progress of metastasis,
shedding some light for further investigation on its signal transduction
pathway. Prenylation transferase inhibitors, which showed an
effective inhibition on cancer cell migration, also suggested a
promising future for the selection of such drugs as anti-cancer agents.
Materials and Methods
Cell culture
Lowly metastatic cell line B16F1 cells were maintained in
DMEM (Dulbecco’s modified Eagle’s medium, Life Technologies
Inc., Grand Island, NY) supplemented with 10% FBS (fetal bovine
serum, Life Technologies Inc.), 100 U/ml penicillin, and 100 mg/
ml streptomycin, and incubated at 37uC in a humidified
atmosphere containing 5% CO2 in the air.
Animals
C57BL/6J mice (6 to 8 weeks old) were obtained from the
Shanghai Laboratory Animal Center (Shanghai, China).
Throughout the experiments, mice were maintained with free
access to pellet food and water in plastic cages at 2162uC and kept
on a 12-hour light-dark cycle. Animal welfare and experimental
procedures were performed strictly in accordance with the
‘‘Principles of laboratory animal care’’ (NIH publication No. 86-
23, revised 1985) and the related ethical regulations of China. All
efforts were made to minimize the animals’ suffering and to reduce
animal consumption.
Construction of vectors and transient transfection in cells
Myc-PRL-3-WT was generated by RT-PCR with the following
primers: sense, 59-GCGGATCCACCATGGAGCAGAAGCT-
GATCTCCGAGGAGGACCTCGCCCGCATGAACCGGCCT-
GCGCCTG-39 and antisense, 59-CTGGTACCCTACATGACG-
CAGCATCTGGTC-39 from muscle total RNA of C57BL/6J
mouse. And mutants were constructed using different antisense
primers: Myc-PRL-3-C170S: 59-CTGGTACCCTACATGACG-
CAGCTTCTGGTCTTGTGCGTGTG-39; Myc-PRL-3-C171S:
59-CTGGTACCCTACATGACGCTGCATCTGGTCTTGTG-
CGTGTG-39; Myc-PRL-3-C170/171S: 59-CTGGTACCCTA-
CATGACGCTGCTTCTGGTCTTGTGCGTGTG-39; Myc-
PRL-3-CCVM-del: 59-CTGGTACCCTATCTGGTCTTGT-
GCGTGTG-39. Then, the PCR fragments were cloned into
BamH I/Kpn I sites of pTARGET (Promega).
Transient transfections were performed to transfer vectors to
B16F1 murine cells. Briefly, 4 ml lipofectamine 2000 (Life
Technologies Inc., Grand Island, NY) and 2 mg plasmids were
diluted in 50 ml MEM (Life Technologies Inc., Grand Island, NY)
and mixed, then incubated at room temperature for 20 minutes
before addition of 900 ml MEM. The mixture was spread onto
cells. Cells were switched to 10% FBS DMEM after 6 hours and
incubated at 37uC for another 18 hours, then collected and
prepared for the following experiments.
Western blot
Western blot assay was performed as described [27]. The B16F1
cells transfected with mock vector, Myc-PRL-3-WT, Myc-PRL-3-
CCVM-del, Myc-PRL-3-C170S, Myc-PRL-3-C171S and Myc-
PRL-3-C170/171S were collected and lysed (50 mM Tris pH 8.0,
150 mM NaCl, 1% NP-40, 0.1% SDS, 5 mM EDTA, 0.1 mM
PMSF (phenylmethylsulfonylfluoride), 0.15 U/ml aprotinin,
1 mg/ml pepstatin and 10% glycerol). Anti-Myc (clone 9E10)
and anti-actin (Santa Cruz Biotechnology) antibodies were used
for the assay.
PRL-3’s Localization
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B16F1 cells transfected with PRL-3-WT or mutants for 24 hours
on glass cover slips were washed with PBS (phosphate-buffered
saline) and fixed with 4% paraformaldehyde on ice for 30 minutes,
followed by permeabilization with 0.1% Triton X-100 for
30 minutes. Cells were blocked with PBS containing 10% serum
for 1 hour at room temperature and then incubated with c-Myc
antibody overnight at 4uC. After washed three times with PBS, cells
were incubated with anti-mouse IgG conjugated with FITC (Sigma)
for 1 hour at room temperature. The expression of fusion proteins
was detected by fluorescence microscope. Nuclei were counter-
stained with 2 g/ml 4,6-diamidino-2-phenylindole (Sigma).
Cell adhesion assay
Cell adhesion assay was performed essentially as described [28]
with some modifications. In brief, 96-well flat-bottom plates were
coated with 50 ml fibronectin (10 mg/ml; Sigma) in PBS overnight
at 4uC and then blocked with 0.2% BSA for 2 hours at room
temperature followed by three times wash. Next, B16F1 cells,
transiently transfected with PRL-3-WT and mutants for 24 hours,
were added into each well in triplicate and incubated for
30 minutes at 37uC. For FTI-277 (Calbiochem) treatment group,
cells were pre-incubated with FTI-277 for 18 hours. Plates were
then washed three times with PBS to remove unbound cells. Cells
remained attaching to the plates were fixed and stained with a
solution containing 0.5% crystal violet and 2% ethanol in 100 mM
borate buffer (pH 9.0). After washing, 100 ml SDS (1% w/v) was
added and the absorbance of the color substrate was measured
with an ELISA reader (TECAN, Austria) at 592 nm. After
subtraction of the background cell binding to BSA-coated wells,
the percentage of adherent cells was calculated by dividing the
optical density of the adherent cells by that of the initial input cells.
Cell migration assay
Cell migration assay was performed using 8.0-mm pore size
Transwell inserts (Costar Corp., Cambridge, MA) as described
previously [3] with some modifications. In brief, the under surface
of the membrane was coated with fibronectin (10 mg/ml) in PBS at
37uC for 2 hours. The membrane was washed in PBS to remove
excess ligand, and the lower chamber was filled with 0.6 ml
DMEM with 10% FBS. Cells were serum-starved overnight (0.5%
FBS), harvested with trypsin/EDTA, and washed twice with
serum-free DMEM. Then cells were re-suspended in migration
medium (DMEM with 0.5% FBS), and 1610
5 cells in 0.1 ml were
added to the upper chamber. For FTI-277 (Calbiochem)
treatment group, cells were pre-incubated with FTI-277 for
18 hours and then added to the upper wells of Transwell inserts,
which still contain FTI-277. After 24 hours at 37uC, the cells on
the upper surface of the membrane were removed by cotton tips.
The migrant cells attached to the lower surface were fixed in
methanol at room temperature for 30 minutes, and stained for
20 minutes with a solution containing 0.5% crystal violet and 2%
ethanol in 100 mM borate buffer (pH 9.0). The number of
migrated cells on the lower surface of the membrane was counted
under a microscope in five fields (1006).
Tail Vein Metastasis Assay
After B16F1 cells were transiently transfected with PRL-3-WT
and mutants, C57BL/6J mice were injected intravenously with
2610
5 cells in 0.1 ml PBS via tail veins. After 20 days, the mice
were euthanized, and their lungs were resected and photographs
were taken (Nikon Coolpix 4500) before fixation in Bouin’s
solution for further analysis. The numbers of metastatic nodules on
the surface of the organs were counted macroscopically.
Histology
Tissues were fixed in Bouin’s solution for 24–48 hours. After
washing with fresh PBS, fixed tissues were dehydrated, cleared,
and embedded in paraffin (Paraplast regular, Sigma). Sections
(5 mm) were collected on microscope slides, deparaffinized, and
stained with H & E as routine procedures.
Statistical analysis
Data were expressed as mean6SEM. Student’s t-test was used
to evaluate the difference between two groups. P,0.05 was
considered to be significant.
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